This week, we turn our attention to what we do in the maintenance setting for management of myeloma. At this point, our patient has gone through initial therapy; for patients who are able to undergo a transplant, we have consolidated their disease with a transplant; and now, we want to maintain that response using a lower dose of therapy, all while trying to minimize toxicity and maximize the patient’s quality of life. We discuss this in detail in this week’s episode!
Content:
- Why is lenolidomide (revlimid) our current standard of care?
- What data do we have to add anti CD38 antibodies?
- How is MRD being considered in this space?
** This episode is sponsored by Primum! To learn more, sign up for your free account, and to ask questions to Primum experts, visit primum.co/fellows
** Want to review the show notes for this episode and others? Check out our website.
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Youtube
